Investors were most concerned yesterday about the one death that occurred in the extension arm of Intercept Pharmaceuticals' CONTROL trial, Citi analyst Joel Beatty said yesterday in a research note. Intercept closed Monday trading down 13% to $117.13. The death isn't overly concerning because a certain number of events would be expected, particularly in a long-term extension study such as this, Beatty wrote. The company told him that the death occurred in a patient who had F4 liver fibrosis at baseline. The analyst does not think the event should have a large impact on Intercept shares. Beatty has a Buy rating on the stock with a $240 price target.